+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Recent advances in non-peptidomimetic dipeptidyl peptidase 4 inhibitors: medicinal chemistry and preclinical aspects



Recent advances in non-peptidomimetic dipeptidyl peptidase 4 inhibitors: medicinal chemistry and preclinical aspects



Current Medicinal Chemistry 19(23): 3982-3999



Dipeptidyl peptidase 4 (DPP-4), a substrate-specific serine protease, has been validated as a promising drug target for the treatment of type 2 diabetes. DPP-4 inhibitors significantly lowered blood glucose levels in patients with type 2 diabetes without common body weight gain, hypoglycemia and gastrointestinal disturbance side effects. Therefore, DPP-4 inhibitors attracted more and more attention. In particular, non-peptidomimetic DPP-4 inhibitors have been a focus of research and development and made great progress in recent years, which resulted in the discovery of a wide variety of potent non-peptidomimetic DPP-4 inhibitors. Some of them, such as sitagliptin, alogliptin and linagliptin have already been used as marketed drugs, while others have been into clinical trials. Based on the core structural features of non-peptidomimetic DPP-4 inhibitors, seven types were classified in the article. For each type, we focused on the description of strategies for design and optimization, together with a discussion on concluded structure-activity relationships (SAR). In addition, the contribution of specific substituents to the inhibition of DPP-4 was summarized. Selectivity towards the inhibition of DPP-4 over dipeptidyl peptidase 8 (DPP-8) and dipeptidyl peptidase 9 (DPP-9) was also presented.

(PDF emailed within 1 workday: $29.90)

Accession: 055398252

Download citation: RISBibTeXText

PMID: 22709010


Related references

Recent approaches to medicinal chemistry and therapeutic potential of dipeptidyl peptidase-4 (DPP-4) inhibitors. European Journal of Medicinal Chemistry 74: 574-605, 2014

Inhibitors of dipeptidyl peptidase IV--recent advances and structural views. Current Topics in Medicinal Chemistry 5(16): 1623-1637, 2005

Synthesis and characterization of constrained peptidomimetic dipeptidyl peptidase IV inhibitors: amino-lactam boroalanines. Journal of Medicinal Chemistry 50(10): 2391-2398, 2007

Medicinal chemistry approaches to the inhibition of dipeptidyl peptidase IV. Current Topics in Medicinal Chemistry 8(17): 1545-1552, 2009

Proteasome inhibitors: recent advances and new perspectives in medicinal chemistry. Current Topics in Medicinal Chemistry 10(3): 232-256, 2010

Preclinical and clinical aspects of the dipeptidyl peptidase-4 inhibitor anagliptin. Nihon Yakurigaku Zasshi. Folia Pharmacologica Japonica 141(6): 339-349, 2013

Medicinal chemistry approaches to the inhibition of dipeptidyl peptidase-4 for the treatment of type 2 diabetes. Bioorganic and Medicinal Chemistry 17(5): 1783-1802, 2009

Recent advances in molecular modeling and medicinal chemistry aspects of phospho-glycoprotein. Current Drug Metabolism 7(2): 205-217, 2006

Dipeptidyl peptidase IV in the immune system. Effects of specific enzyme inhibitors on activity of dipeptidyl peptidase IV and proliferation of human lymphocytes. Biological Chemistry Hoppe-Seyler 372(5): 305-311, 1991

From lead to preclinical candidate: optimization of beta-homophenylalanine based inhibitors of dipeptidyl peptidase IV. Bioorganic and Medicinal Chemistry Letters 19(16): 4818-4823, 2009

Inhibitors of dipeptidyl peptidase 8 and dipeptidyl peptidase 9. Part 1: identification of dipeptide derived leads. Bioorganic and Medicinal Chemistry Letters 18(14): 4154-4158, 2008

Recent patents of dipeptidyl peptidase IV inhibitors. Expert Opinion on Therapeutic Patents 21(11): 1693-1741, 2012

Dipeptidyl peptidase IV (CD26) on human lymphocytes. Synthetic inhibitors of and antibodies against dipeptidyl peptidase IV suppress the proliferation of pokeweed mitogen-stimulated peripheral blood mononuclear cells, and IL-2 and IL-6 production. Immunobiology 188(4-5): 403-414, 1993

Dipeptidyl-peptidase IV, chemistry, biochemistry and physiological aspects. Die Pharmazie 36(7): 518, 1981

In vitro screening for protein tyrosine phosphatase 1B and dipeptidyl peptidase IV inhibitors from selected Nigerian medicinal plants. Journal of Intercultural Ethnopharmacology 6(2): 154-157, 2017